Alaunos Therapeutics Inc. surged as stocks have been trading up by 28.83 percent on optimistic immunotherapy pipeline sentiment.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For TCRT Traders
- Alaunos Therapeutics completed the Velaris Therapeutics acquisition, adding ActRII‑Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
- The company raised about $350M in a concurrent private placement, expected to fund operations into 2029 and advance candidates through proof‑of‑concept and early regulatory filings.
- Proceeds are earmarked to support development of lead pulmonary arterial hypertension candidate VLR199.
- After the deal and financing, TCRT shares jumped about 126% in one report and roughly 225% in another, on extremely heavy trading volume.
- The $350M was raised via a private placement of Series C non‑voting convertible preferred stock.
Live Update At 09:17:22 EDT: On Friday, October 16, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 28.83%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT has gone from sleepy biotech to full‑on momentum name in a matter of days. The daily chart shows Alaunos Therapeutics trading under $1 through late 2026/09, then igniting from $0.78 to a high of $4.40 within three sessions. That is a multi‑bagger move in almost no time, driven by the Velaris Therapeutics acquisition and the $350M private placement headlines.
Even after the spike, recent closes around $2.18 keep TCRT well above its prior range, but also well off the intraday highs — classic for a hot biotech catalyst. Intraday 5‑minute data shows tight action between roughly $2.75 and $3.10, with constant prints and frequent micro‑swings. That tells traders liquidity is strong and scalpers are active.
More Breaking News
- AAL Stock Holds Support As Wall Street Resets Expectations
- KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re‑Rating
- GUTS Stock Reels As Revita Trial Fallout Fuels Class Actions
- SKHY Stock Slides As China DRAM Fears Hit Memory Trade
Fundamentally, Alaunos Therapeutics is still a tiny company. Recent quarterly revenue was just $5,000, with a net loss of about $952,000 and free cash flow of roughly -$300,000. The balance sheet before the raise showed only $124,000 in cash and negative working capital. Those numbers explain why the $350M lifeline is such a big narrative shift for TCRT and why trading interest has exploded.
Why Traders Are Watching TCRT After The Velaris Deal
TCRT just pulled off the kind of one‑two punch catalyst that keeps small‑cap biotech traders glued to their screens. Alaunos Therapeutics closed the acquisition of Velaris Therapeutics and, at the same time, locked in about $350M of fresh capital through a private placement of Series C non‑voting convertible preferred stock. For a company that previously had only $124,000 in cash, that is a total reset.
The Velaris deal drops an entire pipeline of ActRII‑Fc ligand traps and biologics into the Alaunos Therapeutics story, focused on pulmonary arterial hypertension and related cardiopulmonary diseases. For traders, that means TCRT is no longer just a micro‑cap trying to survive quarter to quarter; it is now a better‑capitalized cardiopulmonary platform aiming to push multiple assets through proof‑of‑concept and early regulatory steps.
The market reaction says it all. Reports show Alaunos Therapeutics shares up roughly 126% in one snapshot and about 225% in another, both on extremely heavy volume. That kind of order flow tells you momentum funds, day traders, and swing traders all piled into TCRT at once.
At the same time, this kind of move attracts late chasers and weak hands. With TCRT more than doubling, maybe tripling intraday, the chart is primed for sharp pullbacks and violent bounces. Traders who understand extended moves, VWAP action, and prior high/low levels will treat Alaunos Therapeutics as a trading vehicle, not a long‑term promise. The extended cash runway into 2029 simply lowers near‑term dilution risk and keeps TCRT in play as a story stock.
Conclusion
Alaunos Therapeutics just turned a survival story into an expansion story. By acquiring Velaris Therapeutics and securing about $350M in fresh funding, TCRT now has an extended runway into 2029 and a new pipeline led by VLR199 for pulmonary arterial hypertension. For a company previously posting tiny revenue and sizable losses, that is a dramatic change in backdrop.
For traders, the key is not falling in love with the headlines. TCRT has already delivered a 100%–200% style move on news, and the chart shows wide intraday swings as early entrants lock in profits and new money rotates in. Alaunos Therapeutics will reward discipline — both on entries and exits — because volatility is likely to stay elevated as the market reprices the story. That’s where trade planning and emotional control matter most. As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.” When a ticker like TCRT is moving this fast, those who treat their trading process as a routine rather than a thrill ride are better positioned to stay objective.
This content is for educational and research purposes only, but the trading lesson is clear. As Tim Sykes loves to remind his students, “The market doesn’t care about your opinion, it cares about price action — react to what’s actually happening, not what you hope will happen.” TCRT is now a live case study in that idea: huge catalyst, huge volume, and plenty of opportunity for prepared traders who cut losses fast and respect the risk.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.